IQVIA
About: IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Employees: 88,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1.8% less ownership
Funds ownership: 86.22% [Q3] → 84.42% (-1.8%) [Q4]
9% less funds holding
Funds holding: 1,042 [Q3] → 951 (-91) [Q4]
19% less capital invested
Capital invested by funds: $37.1B [Q3] → $30.1B (-$7B) [Q4]
23% less funds holding in top 10
Funds holding in top 10: 13 [Q3] → 10 (-3) [Q4]
25% less repeat investments, than reductions
Existing positions increased: 310 | Existing positions reduced: 413
28% less first-time investments, than exits
New positions opened: 120 | Existing positions closed: 166
36% less call options, than puts
Call options by funds: $165M | Put options by funds: $260M
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$210
10%
upside
Avg. target
$246
29%
upside
High target
$270
41%
upside
10 analyst ratings
9 positive
90%
1 neutral
10%
0 negative
0%
JP Morgan Anne Samuel 50% 1-year accuracy 18 / 36 met price target | 21%upside $232 | Overweight Maintained | 18 Feb 2025 |
Morgan Stanley Tejas Savant 22% 1-year accuracy 4 / 18 met price target | 31%upside $250 | Overweight Maintained | 11 Feb 2025 |
RBC Capital Sean Dodge 48% 1-year accuracy 19 / 40 met price target | 41%upside $270 | Outperform Reiterated | 10 Feb 2025 |
Truist Securities Jailendra Singh 42% 1-year accuracy 16 / 38 met price target | 38%upside $263 | Buy Reiterated | 10 Feb 2025 |
Stifel Shlomo Rosenbaum 53% 1-year accuracy 10 / 19 met price target | 37%upside $261 | Buy Maintained | 7 Feb 2025 |
Financial journalist opinion
Based on 17 articles about IQV published over the past 30 days
Neutral
Business Wire
22 hours ago
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead.
Neutral
Business Wire
1 day ago
IQVIA Releases 2024 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr.
Neutral
Zacks Investment Research
3 days ago
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Positive
Seeking Alpha
6 days ago
IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way
IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years.
Neutral
Zacks Investment Research
1 week ago
IQVIA (IQV) International Revenue Performance Explored
Explore how IQVIA's (IQV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Positive
Zacks Investment Research
2 weeks ago
IQVIA Earnings & Revenues Surpass Estimates in Q4, Increase Y/Y
Growth in the Research and Development, and Technology and Analytics segments aids IQV's top line in the fourth quarter of 2024.
Neutral
Seeking Alpha
2 weeks ago
IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Kerri Joseph – Senior Vice President, Investor Relations and Treasury Ari Bousbib – Chairman and Chief Executive Officer Ron Bruehlman – Executive Vice President and Chief Financial Officer Conference Call Participants Shlomo Rosenbaum – Stifel Elizabeth Anderson – Evercore ISI Ann Hynes – Mizuho David Windley – Jefferies Charles Rhyee – TD Cowen Jack Meehan – Nephron Research Michael Ryskin – Bank of America Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2024 Earnings Conference Call.
Positive
Benzinga
2 weeks ago
IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions
On Thursday, IQVIA Holdings Inc IQV reported a fourth adjusted EPS of $3.12, up from $2.84, beating the consensus of $3.11.
Positive
Zacks Investment Research
2 weeks ago
Here's What Key Metrics Tell Us About IQVIA (IQV) Q4 Earnings
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
2 weeks ago
IQVIA Holdings (IQV) Beats Q4 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $3.10 per share. This compares to earnings of $2.84 per share a year ago.
Charts implemented using Lightweight Charts™